Texas MPN Workshop 2021 | MPN therapy: present strategies and future directions
Ruben Mesa, MD, Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the direction in which myeloproliferative neoplasm (MPN) therapy is headed, mainly focusing on approaches for the identification of high-risk patient subgroups and for subsequent early intervention. Dr Mesa talks on the use of ropeginterferon for the early intervention of essential thrombocythemia and polycythemia vera to manage symptoms and to halt disease progression in both high- and low-risk patients. In the case of myelofibrosis, combination therapy with agents including JAK inhibitors, LSD1 inhibitors, and BCL-2 inhibitors, are likely to be the standard. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Ruben Mesa, MD, has participated in a consultancy role with Novartis, Sierra Onc, LaJolla, Pharma and Constellation; and has received research support from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior, CTI and Constellation.
